{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:10:45Z","timestamp":1785816645993,"version":"3.56.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The study sought to comprehensively investigate the effect of heart failure (HF) pharmacotherapies in patients with HF with mildly reduced ejection fraction (HFmrEF). In the absence of randomized controlled trials, guideline recommendations concerning HF-related therapies in patients with HFmrEF are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Consecutive patients hospitalized with HFmrEF were retrospectively included at one institution from 2016 to 2022. The prognostic value of treatment with beta-blockers (BB), angiotensin-converting enzyme inhibitors, receptor blockers, or receptor-neprilysin inhibitor (ACEi\/ARB\/ARNI), mineralocorticoid receptor antagonists (MRA), and sodium\u2013glucose-linked transport protein 2 inhibitors (SGLT2i) was investigated for all-cause mortality at 30 months (a median follow-up) and HF-related rehospitalization. A total of 2109 patients with HFmrEF were included. Treatment with BB [27.0 vs. 35.0%; hazard ratio (HR) = 0.737; 95% confidence interval (CI) 0.617\u20130.881; P = 0.001], ACEi\/ARB\/ARNI (25.9 vs. 37.6%; HR = 0.612; 95% CI 0.517\u20130.725; P = 0.001), and SGLT2i (11.9 vs. 29.5%; HR = 0.441; 95% CI 0.236\u20130.824; P = 0.010) was associated with a lower risk of 30-month all-cause mortality, which was still demonstrated after multivariable adjustment and propensity score matching. In contrast, MRA treatment was not associated with long-term prognosis. The risk of HF-related rehospitalization was not affected by HF pharmacotherapies. Finally, the lowest risk of long-term all-cause mortality was observed in patients with combined use of BB, ACEi\/ARB\/ARNI, and SGLT2i (HR = 0.456; 95% CI 0.227\u20130.916; P = 0.027).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Beta-blockers, ACEi\/ARB\/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined \u2018HF triple therapy\u2019. Randomized studies are needed to investigate the effect of HF-related pharmacotherapies in patients with HFmrEF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae121","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T22:56:42Z","timestamp":1711061802000},"page":"1347-1360","source":"Crossref","is-referenced-by-count":13,"title":["Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7617","authenticated-orcid":false,"given":"Tobias","family":"Schupp","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital, Paracelsus Medical University , Prof.-Ernst-Nathan-Stra\u00dfe 1, 90419 Nuremberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielen","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Abel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abumayyaleh","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Akin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Josef-Hospital, Ruhr-Universit\u00e4t Bochum , Gudrunstra\u00dfe 56, 44791 Bochum , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Department of Statistical Analysis, Faculty of Medicine Mannheim, University of Heidelberg , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Weidner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Behnes","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-7115","authenticated-orcid":false,"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"2024082123514325300_zwae121-B1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.hlc.2016.11.021","article-title":"Temporal trends in sudden cardiac death from 1997 to 2010: a data linkage study","volume":"26","author":"Feng","year":"2017","journal-title":"Heart Lung Circ"},{"key":"2024082123514325300_zwae121-B2","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.amjcard.2016.08.065","article-title":"Decade-long trends (2001 to 2011) in the use of evidence-based medical therapies at the time of hospital discharge for patients surviving acute myocardial infarction","volume":"118","author":"Makam","year":"2016","journal-title":"Am J Cardiol"},{"key":"2024082123514325300_zwae121-B3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024082123514325300_zwae121-B4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B5","doi-asserted-by":"crossref","first-page":"e021799","DOI":"10.1161\/JAHA.121.021799","article-title":"Pharmacological treatment following myocardial infarction: how large is the gap between guideline recommendations and routine clinical care?","volume":"10","author":"Schupp","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024082123514325300_zwae121-B6","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"2024082123514325300_zwae121-B7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024082123514325300_zwae121-B8","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.08.2162","article-title":"Ejection fraction pros and cons: JACC state-of-the-art review","volume":"72","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024082123514325300_zwae121-B9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2024082123514325300_zwae121-B10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/jcm11051460","article-title":"Angiotensin converting enzyme inhibitors versus receptor blockers in patients with ventricular tachyarrhythmias","volume":"11","author":"Schupp","year":"2022","journal-title":"J Clin Med"},{"issue":"37","key":"2024082123514325300_zwae121-B14","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024082123514325300_zwae121-B15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ihj.2023.03.003","article-title":"SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis","volume":"75","author":"Banerjee","year":"2023","journal-title":"Indian Heart J"},{"key":"2024082123514325300_zwae121-B16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health Status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024082123514325300_zwae121-B17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.15420\/cfr.2018.11.2","article-title":"Heart failure with mid-range ejection fraction: lessons from CHARM","volume":"4","author":"Lund","year":"2018","journal-title":"Card Fail Rev"},{"key":"2024082123514325300_zwae121-B18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/ehf2.14284","article-title":"The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis","volume":"10","author":"Leite","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2024082123514325300_zwae121-B19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2024082123514325300_zwae121-B20","doi-asserted-by":"crossref","first-page":"e007180","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","article-title":"Association between \u03b2-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease","volume":"13","author":"Fu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2024082123514325300_zwae121-B21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1818","article-title":"Trends in prevalence of comorbidities in heart failure clinical trials","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024082123514325300_zwae121-B22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00392-022-02053-8","article-title":"Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction","volume":"112","author":"Straw","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2024082123514325300_zwae121-B23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2024082123514325300_zwae121-B24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2024082123514325300_zwae121-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-019-00451-0","article-title":"Heart failure with mid-range ejection fraction","volume":"17","author":"Srivastava","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"2024082123514325300_zwae121-B26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.14199","article-title":"Efficacy of guideline-directed medical treatment in heart failure with mildly reduced ejection fraction","volume":"10","author":"Zhang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2024082123514325300_zwae121-B27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/ejechocard\/jep151","article-title":"European association of echocardiography recommendations for training, competence, and quality improvement in echocardiography","volume":"10","author":"Popescu","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2024082123514325300_zwae121-B28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024082123514325300_zwae121-B29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B30","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"2024082123514325300_zwae121-B35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ehjcvp\/pvad036","article-title":"Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction","volume":"9","author":"Stolfo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"2024082123514325300_zwae121-B36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2024082123514325300_zwae121-B37","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2024082123514325300_zwae121-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024082123514325300_zwae121-B39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B40","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2024082123514325300_zwae121-B42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2024082123514325300_zwae121-B43","doi-asserted-by":"crossref","first-page":"e14967","DOI":"10.1097\/MD.0000000000014967","article-title":"Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"98","author":"Xiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2024082123514325300_zwae121-B44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2024082123514325300_zwae121-B45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/pace.14137","article-title":"No impact of mineralocorticoid receptor antagonists on long-term recurrences of ventricular tachyarrhythmias","volume":"44","author":"Schupp","year":"2021","journal-title":"Pacing Clin Electrophysiol"},{"key":"2024082123514325300_zwae121-B46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/08971900211004840","article-title":"Evaluation of the usage and dosing of guideline-directed medical therapy for heart failure with reduced ejection fraction patients in clinical practice","volume":"35","author":"Smith","year":"2022","journal-title":"J Pharm Pract"},{"key":"2024082123514325300_zwae121-B47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cardfail.2021.08.023","article-title":"Comparative effectiveness of dosing of medical therapy for heart failure: from the CHAMP-HF registry","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"key":"2024082123514325300_zwae121-B48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2023.04.022","article-title":"Impact of diabetes mellitus on benefit of \u03b2-blocker therapy after myocardial infarction","volume":"198","author":"Zaatari","year":"2023","journal-title":"Am J Cardiol"},{"key":"2024082123514325300_zwae121-B49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10557-018-6812-z","article-title":"Beta-blockers and ACE inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia","volume":"32","author":"Schupp","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024082123514325300_zwae121-B50","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00380-021-02018-3","article-title":"Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias","volume":"37","author":"Schupp","year":"2022","journal-title":"Heart Vessels"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae121\/57192704\/zwae121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/11\/1347\/58869031\/zwae121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/11\/1347\/58869031\/zwae121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:37:29Z","timestamp":1724294249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/11\/1347\/7633281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,3,21]]},"published-print":{"date-parts":[[2024,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae121","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,21]]}}}